Active inflammatory bowel disease: head-to-head comparison between 99mTc-hexamethylpropylene amine oxime white blood cells and 99mTc(V)-dimercaptosuccinic acid scintigraphy

Nuclear Medicine Communications

Volumn 29, Issue 1, 2008, Pages 27-32

  Stathaki, Maria I ^a   Koutroubakis, Ioannis E ^a   Koukouraki, Sophia I ^a   Karmiris, Konstantinos P ^a   Moschandreas, Joanna A ^a   Kouroumalis, Elias A ^b   Karkavitsas, Nikolaos S ^b  

^a Departments of Nuclear Medicine   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Inflammatory bowel disease

Indexed keywords

DIAGNOSTIC AGENT; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SUCCIMER TC 99M; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; ENTERITIS; FEMALE; HUMAN; LEUKOCYTE; MALE; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; ABSENCE OF SIDE EFFECTS; ANALYTIC METHOD; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DRUG MEGADOSE; GASTROINTESTINAL TRACT SCINTISCANNING; ILIAC CREST; KAPPA STATISTICS; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M DIMERCAPTOSUCCINIC ACID; TECHNETIUM TC 99M EXAMETAZIME;

EID: 39149139658     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1bc37     Document Type: Article

References (31)

1. Parente F, Greco S, Molteni M, Anderloni A, Bianchi Porro G. Imaging inflammatory bowel disease using bowel ultrasound. Eur J Gastroenterol Hepatol 2005; 17:283-291.
2. Scholmerich J, Schmidt E, Schumichen C, Billmann P, Schmidt H, Gerok W. Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxime as leukocyte label. Gastroenterology 1988; 95:1287-1293.
3. Giaffer MH, Tindale WB, Holdsworth D. Value of technetium-99m HMPAO labeled leucocyte scintigraphy as an initial screening test in patients suspected of having inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8:1195-1200.
4. Weldon MJ, Lowe C, Joseph AE, Maxwell JD. Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy. Aliment Pharmacol Ther 1996; 10:123-132.
5. 99mTc-HMPAO labeled leucocytes in inflammatory bowel disease. Eur J Nucl Med 1995; 22:664-670.
6. 99mTc]hexamethylpropyleneamine-oxime-labeled leukocyte scintigraphy in inflammatory bowel disease. Dig Dis Sci 1996; 41:412-420.
7. 99mTc anti-granulocyte antibodies. Eur J Radiol 2000; 35:183-192.
8. 99mTc-LeukoScan in the evaluation of inflammatory bowel disease: a pilot study. Eur J Nucl Med Mol Imaging 2002; 29:251-254.
9. Kapsoritakis AN, Koutroubakis IE, Kouroumalis EA, Koukouraki SI, Karkavitsas N. (99m)Tc-Leucoscan in the evaluation of inflammatory bowel disease. Eur J Nucl Med Mol Imaging 2002; 29:1098.
10. Bhatti M, Chapman P, Peters M, Haskard D, Hodgson HJ. Visualising E-selectin in the detection and evaluation of inflammatory bowel disease. Gut 1998; 43:40-47.
11. Martin-Comin J, Prats E. Clinical applications of radiolabeled blood elements in inflammatory bowel disease. Q J Nucl Med 1999; 43:74-82.
12. Sciarretta G, Furno A, Mazzoni M, Basile C, Malaguti P. Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut 1993; 34:1364-1369.
13. 99mTc-HMPAO granulocyte scintigraphy in the early detection of postoperative asymptomatic recurrence in Crohn's disease. Dig Dis Sci 1997; 42:1549-1556.
14. Sans M, Fuster D, Llach J, Lomena F, Bordas JM, Herranz R, et al. Optimization of technetium-99m-HMPAO leukocyte scintigraphy in evaluation of active inflammatory bowel disease. Dig Dis Sci 2000; 45:1828-1835.
15. 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging and granulocyte scintigraphy with labelled antibodies. Am J Gastroenterol 2002; 97:1978-1985.
16. Lee BF, Chiu NT, Chang JK, Liu GC, Yu HS. Technetium-99m (V)-DMSA and gallium-67 in the assessment of bone and joint infection. J Nucl Med 1998; 39:2128-2131.
17. Ercan MT, Gulaldi NC, Unsal IS, Aydin M, Perkoy I, Hascelik Z. Evaluation of Tc-99m (V) DMSA for imaging inflammatory lesions: an experimental study. Ann Nucl Med 1996; 10:419-423.
18. 99mTc (V) DMSA scintigraphy in the detection and localization of intestinal inflammation: comparison of findings and colonoscopy and biopsy. Radiology 2001; 220:381-385.
19. 99mTc (V) DMSA scintigraphy. Radiology 2003; 229:70-74.
20. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
21. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29-32.
22. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170(suppl):2-6; discussion 16-19.
23. Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991. pp. 132-145.
24. Kolkman JJ, Falke TH, Roos JC, Van Dijk DH, Bannink IM, Den Hollander W, et al. Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findings. Dig Dis Sci 1996; 4:641-650.
25. Molnar T, Papos M, Gyulai C, Ambrus E, Kardos L, Nagy F, et al. Clinical value of technetium-99m-HMPAO-labeled leukocyte scintigraphy and spiral computed tomography in active Crohn's disease. Am J Gastroenterol 2001; 96:1517-1521.
26. 99mTc-WBC vs colonoscopy in the evaluation of inflammation and complications of inflammatory bowel diseases. J Gastroenterol 2002; 37:23-28.
27. Mojiminiyi OA, Udelsman R, Soper ND, Shepstone BJ, Dudley NE. Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid. Clin Nucl Med 1991; 16:259-262.
28. Ohta H, Endo K, Fujita T, Nakajima T, Sakahara H, Torizuka K, et al. Imaging of soft tissue tumours with Tc(V)-99m dimercaptosuccinic acid. A new tumor-seeking agent. Clin Nucl Med 1984; 9:568-573.
29. Kobayashi H, Kotoura Y, Hosono M, Sakahara H, Hosono M, Yao ZS, et al. Diagnostic value of Tc-99m (V) DMSA for chondrogenic tumors with positive Tc99m HMDP uptake on bone scintigraphy. Clin Nucl Med 1995; 20:361-364.
30. Banci M, Bianchi PL, Gianni W, Romani AM, De Vincentis G, Ierardi M, et al. Preliminary evaluation of the usefulness of Tc-99m (V) DMSA in pancreatic neuroendocrine tumors. Clin Nucl Med 1996; 21:122-124.
31. Kobayashi H, Sakahara H, Hosono M, Shirato M, Endo K, Kotoura Y, et al. Soft-tissue tumors: diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy. Radiology 1994; 190:277-280.